Deke,

Keep in mind that no trial of RVX-208 has yet to exceed 6 months in duration. As designed, BETonMACE will have an average treatment period of 18 months, with a range of 12 to 24 months of treatment. Stopping BETonMACE early due to potentially promising RVX-208 efficacy results is unlikely IMO due to the current lack of knowledge regarding the safety of RVX-208 treatment past 6 months. Another possibility is that BETonMACE is halted due to safety concerns. Just playing Devil's advocate here.

Efficacy is only part of the equation. Making sure that no adverse drug-related events occur in the trial is equally important. Efficacy + Safety = Blockbuster?

BearDownAZ